1. A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Issue 2 (8th January 2015) Authors: Heidenreich, Regina; Jasny, Edith; Kowalczyk, Aleksandra; Lutz, Johannes; Probst, Jochen; Baumhof, Patrick; Scheel, Birgit; Voss, Söhnke; Kallen, Karl‐Josef; Fotin‐Mleczek, Mariola Journal: International journal of cancer Issue: Volume 137:Issue 2(2015:Jul. 15) Page Start: 372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Corrigendum to "New vaccination strategies in liver cancer" [Cytokine Growth Factor Rev. 36 (2017) 125–129]. (April 2019) Authors: Mayer-Mokler, Andrea; Flohr, Christian; Reinhardt, Carsten; Singh-Jasuja, Harpreet; Accolla, Roberto; Tosi, Giovanna; Ma, Yuk T.; Adams, David; Valmori, Danila; Heidenreich, Regina; Gnad-Vogt, Ulrike; Königsrainer, Alfred; Löffler, Markus; Rammensee, Hans-Georg; Sangro, Bruno; Francque, Sven; Tag... Journal: Cytokine & growth factor reviews Issue: Volume 46(2019) Page Start: 66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. MRNA mediates passive vaccination against infectious agents, toxins, and tumors. Issue 10 (9th August 2017) Authors: Thran, Moritz; Mukherjee, Jean; Pönisch, Marion; Fiedler, Katja; Thess, Andreas; Mui, Barbara L; Hope, Michael J; Tam, Ying K; Horscroft, Nigel; Heidenreich, Regina; Fotin‐Mleczek, Mariola; Shoemaker, Charles B; Schlake, Thomas Journal: EMBO molecular medicine Issue: Volume 9:Issue 10(2017) Page Start: 1434 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. Issue 13 (22nd March 2019) Authors: Doener, Fatma; Hong, Henoch S.; Meyer, Ingo; Tadjalli-Mehr, Keyvan; Daehling, Angelika; Heidenreich, Regina; Koch, Sven D.; Fotin-Mleczek, Mariola; Gnad-Vogt, Ulrike Journal: Vaccine Issue: Volume 37:Issue 13(2019) Page Start: 1819 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. (4th November 2015) Authors: Heidenreich, Regina; Mehr, Keyvan Tadjalli; Noth, Janine; Koch, Sven; Hong, Henoch; Melber, Karl; Daehling, Angelika; Roos, Tilmann; Lutz, Johannes; Kowalczyk, Aleksandra; Baumhof, Patrick; Scheel, Birgit; Voss, Söhnke; Kallen, Karl-Josef; Fotin-Mleczek, Mariola; Gnad-Vogt, Ulrike Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. Issue 2 (December 2015) Authors: Heidenreich, Regina; Mehr, Keyvan; Noth, Janine; Koch, Sven; Hong, Henoch; Melber, Karl; Daehling, Angelika; Roos, Tilmann; Lutz, Johannes; Kowalczyk, Aleksandra; Baumhof, Patrick; Scheel, Birgit; Voss, Söhnke; Kallen, Karl-Josef; Fotin-Mleczek, Mariola; Gnad-Vogt, Ulrike Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Issue 33 (19th July 2016) Authors: Kowalczyk, Aleksandra; Doener, Fatma; Zanzinger, Kai; Noth, Janine; Baumhof, Patrick; Fotin-Mleczek, Mariola; Heidenreich, Regina Journal: Vaccine Issue: Volume 34:Issue 33(2016) Page Start: 3882 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans. (6th November 2014) Authors: Kowalczyk, Aleksandra; Döner, Fatma; Jasny, Edith; Noth, Janine; Scheel, Birgit; Koch, Sven D; Fotin-Mleczek, Mariola; Heidenreich, Regina Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Self-adjuvanted RNActive® vaccines provide a promising platform for combination therapies with checkpoint inhibitors. (6th November 2014) Authors: Kowalczyk, Aleksandra; Huber, Stephan; Heidenreich, Regina; Fotin-Mleczek, Mariola Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. (December 2017) Authors: Lutz, Johannes; Lazzaro, Sandra; Habbeddine, Mohamed; Schmidt, Kim; Baumhof, Patrick; Mui, Barbara; Tam, Ying; Madden, Thomas; Hope, Michael; Heidenreich, Regina; Fotin-Mleczek, Mariola Journal: Npj vaccines Issue: Volume 2(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗